



FOR IMMEDIATE RELEASE

**Merrimack Pharmaceuticals to Present at
Oppenheimer 19th Annual Healthcare Conference**

CAMBRIDGE, Mass., September 15, 2008 – Merrimack Pharmaceuticals today announced that it will present at the Oppenheimer 19th Annual Healthcare Conference. Robert Mulroy, President and Chief Executive Officer will provide a company overview at 12:40pm EST, Monday, November 3, 2008 at the Waldorf=Astoria in New York.

About Merrimack

Merrimack Pharmaceuticals is an integrated, biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of autoimmune disease and cancer. The company is advancing a robust set of biologics developed from the industry's leading systems biology discovery and development engine. The Company's first oncology product, MM-121, a fully human monoclonal antibody and a first-in-class therapeutic designed to block signaling of the ErbB3 receptor, is in Phase 1 development. Merrimack expects to file an IND early in 2009 on its second oncology product, MM-111, a bi-specific antibody with a targeting arm to ErbB2 and a therapeutic arm to ErbB3, and initiate a Phase 1/2 trial with MM-111 in breast cancer patients who overexpress ErbB2 in mid-2009. Merrimack is headquartered in Cambridge, MA.

Contact:

Kathleen Petrozzelli, Senior Manager, Corporate Communications, 617-441-1043